A Study of Gaboxadol in Primary Insomnia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-06-30

Study Completion Date

2005-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the safety and tolerability of gaboxadol in primary insomnia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To obtain long-term safety and tolerability data with gaboxadol.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Insomnia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Primary insomnia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gaboxadol

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with Primary insomnia

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Please contact: Annelies van der Hammen Legters

Role: STUDY_DIRECTOR

H. Lundbeck A/S

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

99784

Identifier Type: -

Identifier Source: org_study_id